US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% INTC $113.12 ▲+0.55%
FinancialContent

Articles published by Seaport Therapeutics, Inc.

News headline image
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics to Participate in September Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
From Seaport Therapeutics, Inc.
Via Business Wire
Tickers SPTX
News headline image
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
From Seaport Therapeutics, Inc.
Via Business Wire